LXEO
Lexeo Therapeutics, Inc.Company Information
- Company Name
- Lexeo Therapeutics, Inc.
- CIK
- CIK0001907108
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- LXEO: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- LXEO
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-11-25
- Last sale
- 2026-08-18
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 174,817
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 88,347,425
- Shares outstanding
- 85,626,751
- Ownership
- 103.18%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- 0.41%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Convertible Preferred Stock | - | - | - | - | - | - | - | - | - | - | 0 | 85 | ||||||
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 93 | 72 | 63 | 41 | 35 | 29 | 35 | 157 | 175 | 195 | 121 | 35 | ||||||
| Prepaid Expense Current | - | - | - | - | - | - | - | - | - | - | 3 | 1 | ||||||
| Other Assets Current | - | - | - | - | - | - | - | - | - | - | 0 | 2 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 218 | 201 | 188 | 128 | 140 | 105 | 126 | 159 | 177 | 198 | 124 | 39 | ||||||
| Short Term Investments | - | - | - | - | - | 71 | 87 | - | - | - | - | - | ||||||
| Available For Sale Securities Debt Securities Current | 119 | 121 | 119 | 82 | 97 | - | 87 | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 6 | 8 | 7 | 5 | 7 | 5 | 5 | 2 | 2 | 3 | 3 | - | ||||||
| Available For Sale Securities Debt Securities Noncurrent | 22 | 35 | 65 | 0 | 20 | - | 7 | - | - | - | - | - | ||||||
| Equity Securities F V N I Noncurrent | 3 | 3 | 3 | 3 | 3 | - | 0 | - | - | - | - | - | ||||||
| Restricted Cash Noncurrent | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Long Term Investments | - | - | - | - | - | 7 | 7 | - | - | - | - | - | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Finance Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | ||||||
| Operating Lease Right Of Use Asset | 6 | 6 | 7 | 7 | 7 | 8 | 8 | 8 | 9 | 9 | 9 | 10 | ||||||
| Assets | 255 | 250 | 269 | 144 | 176 | 126 | 147 | 174 | 192 | 213 | 140 | 55 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 4 | 3 | 5 | 5 | 20 | 12 | 6 | 8 | 6 | 4 | 4 | 3 | ||||||
| Taxes Payable Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Accrued Bonuses Current | - | - | - | - | - | - | - | - | - | 1 | 3 | 2 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 16 | 14 | 17 | 17 | 32 | 31 | 23 | 27 | 19 | 22 | 17 | 23 | ||||||
| Convertible Notes Payable Current | - | - | - | - | - | - | - | - | - | - | - | 4 | ||||||
| Finance Lease Liability Current | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Liability Current | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Finance Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Liability Noncurrent | 4 | 4 | 5 | 5 | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 8 | ||||||
| Liabilities | 20 | 19 | 22 | 23 | 38 | 38 | 30 | 35 | 27 | 30 | 26 | 32 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Treasury Stock Common Value | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | - | - | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Additional Paid In Capital Common Stock | 662 | 632 | 627 | 480 | 477 | 401 | 397 | 394 | 390 | 386 | 295 | 5 | ||||||
| Stockholders Equity | 235 | 231 | 247 | 121 | 138 | 88 | 117 | 139 | 165 | 183 | 114 | -163 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | -0 | -0 | -0 | - | - | - | - | - | ||||||
| Retained Earnings Accumulated Deficit | -426 | -400 | -380 | -359 | -339 | -313 | -280 | -254 | -225 | -204 | -182 | -168 | ||||||
| Liabilities And Stockholders Equity | 255 | 250 | 269 | 144 | 176 | 126 | 147 | 174 | 192 | 213 | 140 | 55 | ||||||
| Temporary Equity Shares Authorized | - | - | - | - | - | - | - | - | - | - | - | 144 | ||||||
| Temporary Equity Shares Issued | - | - | - | - | - | - | - | - | - | - | - | 144 | ||||||
| Temporary Equity Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 144 | ||||||
| Temporary Equity Liquidation Preference | - | - | - | - | - | - | - | - | - | - | - | 186 | ||||||
| Series B Convertible Preferred Stock | - | - | - | - | - | - | - | - | - | - | 0 | 58 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 18 | ||||||
| Common Stock Shares Issued | 79 | 74 | 73 | 55 | 54 | 33 | 33 | 33 | 33 | 33 | 27 | 2 | ||||||
| Shares Outstanding | 79 | 74 | 73 | 55 | 54 | 33 | 33 | 33 | 33 | 33 | 27 | 2 | ||||||
| Treasury Stock Common Shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialLexeo Therapeutics, Inc. (LXEO) — SEC Financial Statements & Analysis
Lexeo Therapeutics, Inc. (LXEO) is a biological products, (no diagnostic substances) company. Lexeo Therapeutics, Inc. trades on Nasdaq as: LXEO. Lexeo Therapeutics, Inc. (LXEO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Lexeo Therapeutics, Inc. carries a market cap of $398.59M, a P/E ratio of -4.57x, a P/B ratio of 1.70x, an enterprise value of $303.09M, and an EV/EBITDA multiple of -3.20x. On profitability, it posts a Return on Equity (ROE) of -46.76%, a Return on Assets (ROA) of -40.50%, and a Return on Invested Capital (ROIC) of -79.21%. Per share, it reports EPS of $-1.02, diluted EPS of $-1.02, free cash flow per share of $-1.04, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -23.57% year-over-year and EPS growth of -61.10% year-over-year. On the balance sheet, it maintains a current ratio of 13.89x, a quick ratio of 13.49x, working capital of $202.22M, a debt-to-equity ratio of 0.08x, a debt ratio of 0.08, an interest coverage ratio of -1302.97x, free cash flow of $-88.70M (TTM), and net debt of $-95.50M. Figures sourced from SEC EDGAR.
- Market Cap
- $398.59M
- P/E TTM
- -4.57x
- EPS TTM
- $-1.02
- P/B TTM
- 1.70x
- ROE TTM
- -46.76%
- ROA TTM
- -40.50%
- Debt To Equity
- 0.08x
- Free Cash Flow TTM
- $-88.70M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Lexeo Therapeutics, Inc. in?
Lexeo Therapeutics, Inc. (LXEO) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does LXEO trade on?
Lexeo Therapeutics, Inc. (LXEO) trades on the Nasdaq.
When was Lexeo Therapeutics, Inc. (LXEO)'s most recent SEC filing?
Lexeo Therapeutics, Inc. (LXEO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is LXEO's market cap?
Lexeo Therapeutics, Inc. (LXEO) has a market capitalization of $398.59M as of 2026-06-30.
What is LXEO's EPS (earnings per share)?
Lexeo Therapeutics, Inc. (LXEO)'s trailing twelve month EPS is $-1.02 as of 2026-06-30.
What is LXEO's ROE (return on equity)?
Lexeo Therapeutics, Inc. (LXEO)'s trailing twelve month Return on Equity (ROE) is -46.76% as of 2026-06-30.
What is LXEO's ROA (return on assets)?
Lexeo Therapeutics, Inc. (LXEO)'s trailing twelve month Return on Assets (ROA) is -40.50% as of 2026-06-30.
What is LXEO's ROIC (return on invested capital)?
Lexeo Therapeutics, Inc. (LXEO)'s trailing twelve month Return on Invested Capital (ROIC) is -79.21% as of 2026-06-30.
What is LXEO's EV/EBITDA?
Lexeo Therapeutics, Inc. (LXEO)'s trailing twelve month EV/EBITDA is -3.20x as of 2026-06-30.